Table Info

Table 1.

RMSD (Å) of glycan conformations in different antibody binding states

System	Glycan	Ave	Sd	Min	Max
Antibody	Chain A	2.2	0.8	0.6	4.6
Antibody	Chain B	2.1	0.6	0.8	4.2
Antibody-antigen	Chain A	1.8	0.6	0.6	4.4
Antibody-antigen	Chain B	2.0	0.5	0.7	4.2
Antibody-hFcγRI	Chain A	2.2	0.9	0.6	5.0
	Chain B	1.9	0.5	0.9	3.8
	Chain A	1.6	0.5	0.6	5.2
	Chain B	2.0	0.6	0.8	3.9

Ave: average RMSD; Sd: standard deviation; Min: minimum RMSD; Max: maximum RMSD

Supplementary materials

The supplementary materials for this article are available at: https://www.explorationpub.com/uploads/Article/file/10034_sup_1.pdf.

Declarations

Acknowledgments

BM thanks Dr. Jun Zhao for helpful discussion.

Author contributions

The author contributed solely to the work.

Conflicts of interest

The author declares that there are no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

BM thanks Shanghai Jiaotong University for supporting this work. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Frank M, Walker RC, Lanzilotta WN, Prestegard JH, Barb AW. Immunoglobulin G1 Fc domain motions: implications for Fc engineering. J Mol Biol. 2014;426:1799–811. [DOI] [PubMed] [PMC]

Zhang Y. Understanding the impact of Fc glycosylation on its conformational changes by molecular dynamics simulations and bioinformatics. Mol Biosys. 2015;11:3415–24. [DOI]

Mimura Y, Sondermann P, Ghirlando R, Lund J, Young SP, Goodall M, et al. Role of oligosaccharide residues of IgG1-Fc in Fc gamma RIIb binding. J Biol Chem. 2001;276:45539–47. [DOI] [PubMed]

Lu J, Chu J, Zou Z, Hamacher NB, Rixon MW, Sun PD. Structure of FcgammaRI in complex with Fc reveals the importance of glycan recognition for high-affinity IgG binding. Proc Natl Acad Sci U S A. 2015;112:833–8. [DOI] [PubMed] [PMC]

Lund J, Tanaka T, Takahashi N, Sarmay G, Arata Y, Jefferis R. A protein structural change in aglycosylated IgG3 correlates with loss of huFc gamma R1 and huFc gamma R111 binding and/or activation. Mol Immunol. 1990;27:1145–53. [DOI] [PubMed]

Walker MR, Lund J, Thompson KM, Jefferis R. Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing Fc gamma RI and/or Fc gamma RII receptors. Biochem J. 1989;259:347–53. [DOI] [PubMed] [PMC]

Jefferis R. The glycosylation of antibody molecules: functional significance. Glycoconj J. 1993;10:358–61. [PubMed]

Li W, Yu R, Ma B, Yang Y, Jiao X, Liu Y, et al. Core fucosylation of IgG B cell receptor is required for antigen recognition and antibody production. J Immunol. 2015;194:2596–606. [DOI] [PubMed]

Wang Z, Zhu J, Lu H. Antibody glycosylation: impact on antibody drug characteristics and quality control. Appl Microbiol Biotechnol. 2020;104:1905–14. [DOI] [PubMed]

10.

Lund J, Takahashi N, Pound JD, Goodall M, Jefferis R. Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains. J Immunol. 1996;157:4963–9. [PubMed]

11.

Yu X, Baruah K, Harvey DJ, Vasiljevic S, Alonzi DS, Song BD, et al. Engineering hydrophobic protein-carbohydrate interactions to fine-tune monoclonal antibodies. J Am Chem Soc. 2013;135:9723–32. [DOI] [PubMed] [PMC]

12.

Ahmed AA, Giddens J, Pincetic A, Lomino JV, Ravetch JV, Wang LX, et al. Structural characterization of anti-inflammatory immunoglobulin G Fc proteins. J Mol Biol. 2014;426:3166–79. [DOI] [PubMed] [PMC]

13.

Barb AW, Prestegard JH. NMR analysis demonstrates immunoglobulin G N-glycans are accessible and dynamic. Nat Chem Biol. 2011;7:147–53. [DOI] [PubMed] [PMC]

14.

Barb AW, Meng L, Gao Z, Johnson RW, Moremen KW, Prestegard JH. NMR characterization of immunoglobulin G Fc glycan motion on enzymatic sialylation. Biochemistry. 2012;51:4618–26. [DOI] [PubMed] [PMC]

15.

Okbazghi SZ, More AS, White DR, Duan S, Shah IS, Joshi SB, et al. Production, characterization, and biological evaluation of well-defined IgG1 Fc glycoforms as a model system for biosimilarity analysis. J Pharm Sci. 2016;105:559–74. [DOI] [PubMed] [PMC]

16.

Subedi GP, Barb AW. The immunoglobulin G1 N-glycan composition affects binding to each low affinity Fc gamma receptor. MAbs. 2016;8:1512–24. [DOI] [PubMed] [PMC]

17.

Yamaguchi Y, Nishimura M, Nagano M, Yagi H, Sasakawa H, Uchida K, et al. Glycoform-dependent conformational alteration of the Fc region of human immunoglobulin G1 as revealed by NMR spectroscopy. Biochim Biophys Acta. 2006;1760:693–700. [DOI] [PubMed]

18.

Shields RL, Lai J, Keck R, O’Connell LY, Hong K, Meng YG, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem. 2002;277:26733–40. [DOI] [PubMed]

19.

Lee HS, Im W. Effects of N-glycan composition on structure and dynamics of IgG1 Fc and their implications for antibody engineering. Sci Rep. 2017;7:12659. [DOI] [PubMed] [PMC]

20.

Deisenhofer J. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. Biochemistry. 1981;20:2361–70. [PubMed]

21.

Kiyoshi M, Caaveiro JMM, Kawai T, Tashiro S, Ide T, Asaoka Y, et al. Structural basis for binding of human IgG1 to its high-affinity human receptor FcgammaRI. Nat Commun. 2015;6:6866. [DOI] [PubMed] [PMC]

22.

Sakae Y, Satoh T, Yagi H, Yanaka S, Yamaguchi T, Isoda Y, et al. Conformational effects of N-glycan core fucosylation of immunoglobulin G Fc region on its interaction with Fcgamma receptor IIIa. Sci Rep. 2017;7:13780. [DOI] [PubMed] [PMC]

23.

Yanaka S, Yogo R, Inoue R, Sugiyama M, Itoh SG, Okumura H, et al. Dynamic views of the Fc region of immunoglobulin G provided by experimental and computational observations. Antibodies (Basel). 2019;8:39. [DOI]

24.

Zhao J, Nussinov R, Ma B. Antigen binding allosterically promotes Fc receptor recognition. MAbs. 2019;11:58–74. [DOI] [PubMed] [PMC]

25.

Harris LJ, Larson SB, Hasel KW, McPherson A. Refined structure of an intact IgG2a monoclonal antibody. Biochemistry. 1997;36:1581–97. [DOI] [PubMed]

26.

Crespi GA, Hermans SJ, Parker MW, Miles LA. Molecular basis for mid-region amyloid-beta capture by leading Alzheimer’s disease immunotherapies. Sci Rep. 2015;5:9649. [DOI] [PubMed] [PMC]

27.

Kalé L, Skeel R, Bhandarkar M, Brunner R, Gursoy A, Krawetz N, et al. NAMD2: greater scalability for parallel molecular dynamics. J Comput Phys. 1999;151:283–312. [DOI]

28.

MacKerell AD, Bashford D, Bellott M, Dunbrack RL, Evanseck JD, Field MJ, et al. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B. 1998;102:3586–616. [DOI] [PubMed]

29.

Zhao J, Nussinov R, Ma B. Mechanisms of recognition of Abeta monomer, oligomer, and fibril by homologous antibodies. J Biol Chem. 2017;292:44. [DOI]

30.

Lua WH, Ling WL, Yeo JY, Poh JJ, Lane DP, Gan SK. The effects of Antibody Engineering CH and CL in Trastuzumab and Pertuzumab recombinant models: impact on antibody production and antigen-binding. Sci Rep. 2018;8:718. [DOI] [PubMed] [PMC]

31.

Sela-Culang I, Alon S, Ofran Y. A systematic comparison of free and bound antibodies reveals binding-related conformational changes. J Immunol. 2012;189:4890–9. [DOI] [PubMed]

32.

Adachi M, Kurihara Y, Nojima H, Takeda-Shitaka M, Kamiya K, Umeyama H. Interaction between the antigen and antibody is controlled by the constant domains: normal mode dynamics of the HEL-HyHEL-10 complex. Protein Sci. 2003;12:2125–31. [DOI] [PubMed] [PMC]

33.

Pritsch O, Hudry-Clergeon G, Buckle M, Petillot Y, Bouvet JP, Gagnon J, et al. Can immunoglobulin C (H) 1 constant region domain modulate antigen binding affinity of antibodies? J Clin Invest. 1996;98:2235. [DOI] [PubMed] [PMC]

34.

Dam TK, Torres M, Brewer CF, Casadevall A. Isothermal titration calorimetry reveals differential binding thermodynamics of variable region-identical antibodies differing in constant region for a univalent ligand. J Biol Chem. 2008;283:31366–70. [DOI] [PubMed] [PMC]

35.

Tudor D, Yu H, Maupetit J, Drillet AS, Bouceba T, Schwartz-Cornil I, et al. Isotype modulates epitope specificity, affinity, and antiviral activities of anti-HIV-1 human broadly neutralizing 2F5 antibody. Proc Natl Acad Sci U S A. 2012;109:12680–5. [DOI] [PubMed] [PMC]

36.

Li T, Tracka MB, Uddin S, Casas-Finet J, Jacobs DJ, Livesay DR. Rigidity emerges during antibody evolution in three distinct antibody systems: evidence from QSFR analysis of Fab fragments. PLoS Comput Biol. 2015;11:e1004327. [DOI] [PubMed] [PMC]

37.

Janda A, Bowen A, Greenspan NS, Casadevall A. Ig constant region effects on variable region structure and function. Front Microbiol. 2016;7:22. [DOI] [PubMed] [PMC]

38.

Janda A, Casadevall A. Circular Dichroism reveals evidence of coupling between immunoglobulin constant and variable region secondary structure. Mol Immunol. 2010;47:1421–5. [DOI] [PubMed] [PMC]

39.

Janda A, Eryilmaz E, Nakouzi A, Cowburn D, Casadevall A. Variable region identical immunoglobulins differing in isotype express different paratopes. J Biol Chem. 2012;287:35409–17. [DOI] [PubMed] [PMC]

40.

Correa A, Trajtenberg F, Obal G, Pritsch O, Dighiero G, Oppezzo P, et al. Structure of a human IgA1 Fab fragment at 1.55 Å resolution: potential effect of the constant domains on antigen-affinity modulation. Acta Crystallogr D Biol Crystallogr. 2013;69:388–97. [DOI] [PubMed]

41.

Tomaras GD, Ferrari G, Shen X, Alam SM, Liao HX, Pollara J, et al. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci U S A. 2013;110:9019–24. [DOI] [PubMed] [PMC]

42.

Cooper LJ, Shikhman AR, Glass DD, Kangisser D, Cunningham MW, Greenspan NS. Role of heavy chain constant domains in antibody-antigen interaction. Apparent specificity differences among streptococcal IgG antibodies expressing identical variable domains. J Immunol. 1993;150:2231–42. [PubMed]

43.

Torosantucci A, Chiani P, Bromuro C, De Bernardis F, Palma AS, Liu Y, et al. Protection by anti-beta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherence. PLoS One. 2009;4:e5392. [DOI] [PubMed] [PMC]

44.

Kato K, Matsunaga C, Odaka A, Yamato S, Takaha W, Shimada I, et al. Carbon-13 NMR study of switch variant anti-dansyl antibodies: antigen binding and domain-domain interactions. Biochemistry. 1991;30:6604–10. [DOI] [PubMed]

45.

Torres M, May R, Scharff MD, Casadevall A. Variable-region-identical antibodies differing in isotype demonstrate differences in fine specificity and idiotype. J Immunol. 2005;174:2132–42. [DOI] [PubMed]

46.

Su C, Lua W, Ling W, Gan SK. Allosteric effects between the antibody constant and variable regions: a study of IgA Fc mutations on antigen binding. Antibodies. 2018;7:20. [DOI]

47.

Brown EP, Dowell KG, Boesch AW, Normandin E, Mahan AE, Chu T, et al. Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles. J Immunol Methods. 2017;443:33–44. [DOI] [PubMed] [PMC]

48.

Yang D, Kroe-Barrett R, Singh S, Roberts CJ, Laue TM. IgG cooperativity--Is there allostery? Implications for antibody functions and therapeutic antibody development. MAbs. 2017;9:1231–52. [DOI] [PubMed] [PMC]